Key Details
Price
$2.90Annual ROE
-12.53%Beta
1.96Events Calendar
Next earnings date:
Feb 28, 2025Recent quarterly earnings:
Nov 06, 2024Recent annual earnings:
Feb 29, 2024Next ex-dividend date:
N/ARecent ex-dividend date:
N/ANext split:
N/ARecent split:
N/AAnalyst ratings
Recent major analysts updates
07 Nov '24 RBC Capital
Outperform22 Oct '24 Wedbush
Outperform16 Sept '24 HC Wainwright & Co.
Buy11 Sept '24 Wedbush
Outperform06 Aug '24 RBC Capital
Outperform17 July '24 HC Wainwright & Co.
Buy03 June '24 HC Wainwright & Co.
Buy24 May '24 Wedbush
Outperform22 May '24 HC Wainwright & Co.
Buy15 May '24 Wedbush
OutperformMarket Data
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Dividend
Nuvation Bio doesn't have historical dividend data
Profitability
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Efficiency
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Valuation
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Liquidity
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Cash Flow
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Institutional Ownership
Positive Pooled Data from Nuvation Bio's TRUST-I and TRUST-II Studies Highlight Taletrectinib's Best-in-Class Potential for Patients with Advanced ROS1-positive NSCLC, Supporting Planned New Drug Application Submission in the Fourth Quarter of 2024
NUVB
businesswire.com14 September 2024
NEW YORK--(BUSINESS WIRE)--Nuvation Bio Inc. (NYSE: NUVB), a late clinical-stage, global biopharmaceutical company tackling some of the greatest unmet needs in oncology, today announced positive pooled data from the pivotal Phase 2 TRUST-I and TRUST-II studies evaluating taletrectinib, an investigational next-generation ROS1 TKI. The findings will be highlighted in a poster presentation on September 14, 2024, at the European Society of Medical Oncology (ESMO) Congress 2024 in Barcelona, Spain.
Nuvation Bio Inc. (NUVB) Is Up 25.28% in One Week: What You Should Know
NUVB
Zacks Investment Research08 March 2024
Does Nuvation Bio Inc. (NUVB) have what it takes to be a top stock pick for momentum investors? Let's find out.
FAQ
- What is the primary business of Nuvation Bio?
- What is the ticker symbol for Nuvation Bio?
- Does Nuvation Bio pay dividends?
- What sector is Nuvation Bio in?
- What industry is Nuvation Bio in?
- What country is Nuvation Bio based in?
- When did Nuvation Bio go public?
- Is Nuvation Bio in the S&P 500?
- Is Nuvation Bio in the NASDAQ 100?
- Is Nuvation Bio in the Dow Jones?
- When was Nuvation Bio's last earnings report?
- When does Nuvation Bio report earnings?
- Should I buy Nuvation Bio stock now?
What is the primary business of Nuvation Bio?
Nuvation Bio (NUVB) is a biotechnology company focused on developing innovative cancer therapies. They aim to create new treatments that improve patient outcomes by targeting specific cancer mechanisms. Nuvation Bio combines advanced science with a commitment to addressing unmet medical needs in oncology.
What is the ticker symbol for Nuvation Bio?
The ticker symbol for Nuvation Bio is NYSE:NUVB
Does Nuvation Bio pay dividends?
No, Nuvation Bio does not pay dividends
What sector is Nuvation Bio in?
Nuvation Bio is in the Healthcare sector
What industry is Nuvation Bio in?
Nuvation Bio is in the Biotechnology industry
What country is Nuvation Bio based in?
Nuvation Bio is headquartered in United States
When did Nuvation Bio go public?
Nuvation Bio's initial public offering (IPO) was on 26 August 2020
Is Nuvation Bio in the S&P 500?
No, Nuvation Bio is not included in the S&P 500 index
Is Nuvation Bio in the NASDAQ 100?
No, Nuvation Bio is not included in the NASDAQ 100 index
Is Nuvation Bio in the Dow Jones?
No, Nuvation Bio is not included in the Dow Jones index
When was Nuvation Bio's last earnings report?
Nuvation Bio's most recent earnings report was on 6 November 2024
When does Nuvation Bio report earnings?
The next expected earnings date for Nuvation Bio is 28 February 2025
Should I buy Nuvation Bio stock now?
As of today, analysts generally recommend a 'Strong buy' rating. However, it's important to do your own research and consider your financial situation before making any investment decisions